CA2255826A1 - Mutated nonactivating igg2 domains and anti-cd3 antibodies incorporating the same - Google Patents

Mutated nonactivating igg2 domains and anti-cd3 antibodies incorporating the same

Info

Publication number
CA2255826A1
CA2255826A1 CA002255826A CA2255826A CA2255826A1 CA 2255826 A1 CA2255826 A1 CA 2255826A1 CA 002255826 A CA002255826 A CA 002255826A CA 2255826 A CA2255826 A CA 2255826A CA 2255826 A1 CA2255826 A1 CA 2255826A1
Authority
CA
Canada
Prior art keywords
antibodies
same
mutated
nonactivating
antibodies incorporating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002255826A
Other languages
French (fr)
Other versions
CA2255826C (en
Inventor
J. Yun Tso
Michael S. Cole
Claudio Anasetti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Biotherapeutics Inc
Fred Hutchinson Cancer Center
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2255826A1 publication Critical patent/CA2255826A1/en
Application granted granted Critical
Publication of CA2255826C publication Critical patent/CA2255826C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Abstract

The invention provides mutated IgG2 constant regions and anti-CD3 antibodies incorporating the same. Such antibodies specifically bind to the CD3 antigen on T-cells but induce reduced mitogenic response compared with otherwise identical antibodies bearing natural IgG2 constant regions. The antibodies can be used for treating disorders requiring immune suppression with fewer side effects than result from treatment with prior anti-CD3 antibodies.
CA002255826A 1996-05-20 1997-05-19 Mutated nonactivating igg2 domains and anti-cd3 antibodies incorporating the same Expired - Lifetime CA2255826C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US65041096A 1996-05-20 1996-05-20
US08/650,410 1996-05-20
US08/656,586 1996-05-31
US08/656,586 US5834597A (en) 1996-05-20 1996-05-31 Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
PCT/US1997/008576 WO1997044362A1 (en) 1996-05-20 1997-05-19 MUTATED NONACTIVATING IgG2 DOMAINS AND ANTI-CD3 ANTIBODIES INCORPORATING THE SAME

Publications (2)

Publication Number Publication Date
CA2255826A1 true CA2255826A1 (en) 1997-11-27
CA2255826C CA2255826C (en) 2002-10-01

Family

ID=27095860

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002255826A Expired - Lifetime CA2255826C (en) 1996-05-20 1997-05-19 Mutated nonactivating igg2 domains and anti-cd3 antibodies incorporating the same

Country Status (11)

Country Link
US (1) US5834597A (en)
EP (1) EP0966485B1 (en)
JP (2) JP3947570B2 (en)
CN (1) CN100549031C (en)
AT (1) ATE407952T1 (en)
AU (1) AU725821B2 (en)
CA (1) CA2255826C (en)
DE (1) DE69738984D1 (en)
ES (1) ES2313736T3 (en)
PT (1) PT966485E (en)
WO (1) WO1997044362A1 (en)

Families Citing this family (298)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
WO1998047531A2 (en) * 1997-04-21 1998-10-29 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
IL138608A0 (en) * 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
KR20060067983A (en) * 1999-01-15 2006-06-20 제넨테크, 인크. Polypeptide variants with altered effector function
DE19905048A1 (en) * 1999-02-08 2000-08-10 Gsf Forschungszentrum Umwelt Use of depletoric or mitogenic antibodies in immunotherapy
DE19905012A1 (en) * 1999-02-08 2000-08-10 Gsf Forschungszentrum Umwelt Medicines containing anti-CD3 and anti-Fcgamma-R antibodies for accompanying treatment in organ transplants
US6972125B2 (en) * 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
CN1360596A (en) * 1999-02-12 2002-07-24 遗传研究所有限公司 Humanized immunoglobulin reactive with B7 molecules and methods of treatment therewith
EP1085453A1 (en) * 1999-09-20 2001-03-21 TELEFONAKTIEBOLAGET LM ERICSSON (publ) SIM card holder
CN1461310B (en) 2000-02-10 2013-06-12 雅培制药有限公司 ANtibodies that bind human interleukin-18 and methods of making and using
US7416726B2 (en) 2000-04-13 2008-08-26 The Rockefeller University Enhancement of antibody-mediated immune responses
US20080095774A1 (en) * 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
GB2380127A (en) * 2001-09-26 2003-04-02 Isis Innovation Treatment of chronic joint inflammation
JP2005512044A (en) * 2001-12-03 2005-04-28 アブジェニックス・インコーポレーテッド Antibody classification based on binding properties
ATE374944T1 (en) * 2001-12-03 2007-10-15 Abgenix Inc IDENTIFICATION OF HIGH-AFFINE MOLECULES THROUGH LIMITED DILUTION SCREENING
EP1466177A4 (en) * 2001-12-03 2005-08-17 Abgenix Inc Discovery of therapeutic products
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20070148171A1 (en) * 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20080254027A1 (en) * 2002-03-01 2008-10-16 Bernett Matthew J Optimized CD5 antibodies and methods of using the same
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20030216551A1 (en) * 2002-03-08 2003-11-20 Diabetogen Biosciences Inc. Fully human anti-CD3 monoclonal antibodies
SE0200943D0 (en) * 2002-03-25 2002-03-25 Amersham Biosciences Ab Mutant protein
CA2481747A1 (en) * 2002-04-12 2003-10-23 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
BR0311471A (en) * 2002-05-30 2007-04-27 Macrogenics Inc anti-cd16a antibody, and methods for reducing a deleterious immune response in a mammal and treating a deleterious immune response in a mammal
EP1542721A4 (en) * 2002-06-14 2007-05-02 Centocor Inc Modified "s" antibodies
US20030235583A1 (en) * 2002-06-14 2003-12-25 Jeppe Sturis Combined use of a modulator of CD3 and a beta cell resting compound
AU2003232171A1 (en) * 2002-06-14 2003-12-31 Novo Nordisk A/S Combined use of a modulator of cd3 and a beta cell resting compound
US20040037826A1 (en) * 2002-06-14 2004-02-26 Michelsen Birgitte Koch Combined use of a modulator of CD3 and a GLP-1 compound
EP1515749B1 (en) * 2002-06-14 2012-08-15 Novo Nordisk A/S Combined use of a modulator of cd3 and a glp-1 compound
AR040778A1 (en) * 2002-08-06 2005-04-20 Glaxo Group Ltd ALTERED ANTIBODIES OR FUNCTIONAL FRAGMENTS THAT BIND MAG (GLICOPROTEIN ASSOCIATED WITH HONEY).
US8530627B2 (en) 2002-08-14 2013-09-10 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8187593B2 (en) 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US7361740B2 (en) * 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217797B2 (en) * 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7365168B2 (en) * 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217798B2 (en) * 2003-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of Fc-fusion protein serum half-lives by mutagenesis
WO2004052397A1 (en) * 2002-12-05 2004-06-24 Protein Design Labs, Inc. Methods of treatment of ulcerative colitis with anti-cd3 antibodies
BRPI0317376B8 (en) * 2002-12-17 2021-05-25 Merck Patent Gmbh antibody-il2 fusion protein designated as hu14.18-il2, uses thereof, vector and pharmaceutical composition
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP1587540B1 (en) 2003-01-09 2021-09-15 MacroGenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
WO2005011619A2 (en) * 2003-01-31 2005-02-10 Five Prime Therapeutics, Inc. Lung-expressed polypeptides
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20070275460A1 (en) * 2003-03-03 2007-11-29 Xencor.Inc. Fc Variants With Optimized Fc Receptor Binding Properties
CN1798767B (en) * 2003-04-10 2011-02-16 晶面生物技术公司 Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
KR20120035234A (en) * 2003-04-11 2012-04-13 메디뮨 엘엘씨 Recombinant il-9 antibodies and uses thereof
CU23403A1 (en) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular RECOMBINANT ANTIBODIES AND FRAGMENTS RECOGNIZING GANGLIOSIDE N-GLICOLIL GM3 AND ITS USE FOR DIAGNOSIS AND TUMOR TREATMENT
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
US7700097B2 (en) * 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
EP2397189B1 (en) * 2003-11-14 2015-03-18 Brigham and Women's Hospital, Inc. Methods of modulating immunity
EP1697520A2 (en) * 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
CA2554978A1 (en) * 2004-02-04 2005-08-25 The Trustees Of Columbia University In The City Of New York Anti-cd3 and antigen-specific immunotherapy to treat autoimmunity
US7276585B2 (en) * 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
CA2569240A1 (en) * 2004-06-01 2005-12-15 Domantis Limited Drug fusion comprising a polypeptide drug and an immunoglobulin heavy chain variable domain specific for serum albumin
KR20120064120A (en) 2004-06-01 2012-06-18 제넨테크, 인크. Antibody drug conjugates and methods
AU2005250499B2 (en) * 2004-06-03 2011-12-08 Novimmune S.A. Anti-CD3 antibodies and methods of use thereof
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
ES2426817T3 (en) 2004-08-04 2013-10-25 Mentrik Biotech, Llc Fc regions variants
WO2006031994A2 (en) * 2004-09-14 2006-03-23 Xencor, Inc. Monomeric immunoglobulin fc domains
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP1817340B1 (en) 2004-11-12 2012-05-16 Xencor, Inc. Fc variants with altered binding to fcrn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
JP5185624B2 (en) 2004-12-02 2013-04-17 ドマンティス リミテッド Bispecific antibodies targeting serum albumin and GLP-1 or PYY
DK1831258T4 (en) 2004-12-28 2023-08-28 Innate Pharma Sa Monoklonale antistoffer mod NKG2A
CA2595169A1 (en) * 2005-01-12 2006-07-20 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
JP2008531049A (en) * 2005-02-28 2008-08-14 セントカー・インコーポレーテツド Heterodimeric protein binding composition
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
AU2006236439B2 (en) 2005-04-15 2012-05-03 Macrogenics, Inc. Covalent diabodies and uses thereof
US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof
US9889197B2 (en) 2005-04-15 2018-02-13 Macrogenics, Inc. Covalently-associated diabody complexes that possess charged coil domains and that are capable of enhanced binding to serum albumin
JP5105485B2 (en) 2005-08-10 2012-12-26 マクロジェニクス,インコーポレーテッド Identification and engineering modification of antibodies having mutant Fc region and methods of use thereof
AU2006291005A1 (en) * 2005-09-12 2007-03-22 Novimmune S.A. Anti-CD3 antibody formulations
EP1931709B1 (en) 2005-10-03 2016-12-07 Xencor, Inc. Fc variants with optimized fc receptor binding properties
US7973136B2 (en) * 2005-10-06 2011-07-05 Xencor, Inc. Optimized anti-CD30 antibodies
AR059922A1 (en) 2006-04-01 2008-05-07 Galaxy Biotech Llc HUMANIZED MONOCLONAL ANTIBODIES FOR THE GROWTH FACTOR OF HEPATOCITS
US7786270B2 (en) 2006-05-26 2010-08-31 Macrogenics, Inc. Humanized FcγRIIB-specific antibodies and methods of use thereof
NZ597251A (en) 2006-05-30 2013-08-30 Genentech Inc Antibodies and immunoconjugates and uses therefor
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
CA2653387A1 (en) * 2006-06-06 2007-12-21 Tolerrx, Inc. Administration of anti-cd3 antibodies in the treatment of autoimmune diseases
SG177907A1 (en) 2006-06-14 2012-02-28 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
AU2007281876B2 (en) 2006-06-26 2013-09-05 Macrogenics, Inc. FcgammaRIIB-specific antibodies and methods of use thereof
WO2008002933A2 (en) 2006-06-26 2008-01-03 Macrogenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
JP5825756B2 (en) 2006-08-14 2015-12-02 ゼンコー・インコーポレイテッドXencor、 Inc. Optimized antibody targeting CD19
US8394374B2 (en) 2006-09-18 2013-03-12 Xencor, Inc. Optimized antibodies that target HM1.24
BRPI0718118A2 (en) 2006-10-27 2017-05-30 Lpath Inc compositions and methods for sphingosine-1-phosphate binding
CA2667706A1 (en) 2006-10-27 2008-05-08 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
RS53942B1 (en) 2006-10-27 2015-08-31 Genentech Inc. Antibodies and immunoconjugates and uses therefor
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
JP2010513539A (en) * 2006-12-20 2010-04-30 エムエムアール インフォメーション システムズ,インコーポレーテッド Antibodies and their production and use
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
CA2724432A1 (en) 2007-05-30 2008-12-11 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
US7580304B2 (en) * 2007-06-15 2009-08-25 United Memories, Inc. Multiple bus charge sharing
PE20120259A1 (en) 2007-08-09 2012-04-04 Boehringer Ingelheim Int ANTI-CD37 ANTIBODIES
US8361465B2 (en) * 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
WO2015164330A1 (en) 2014-04-21 2015-10-29 Millennium Pharmaceuticals, Inc. Anti-psyk antibody molecules and use of same for syk-targeted therapy
US8795667B2 (en) 2007-12-19 2014-08-05 Macrogenics, Inc. Compositions for the prevention and treatment of smallpox
EP3045475B1 (en) 2008-04-02 2017-10-04 MacroGenics, Inc. Bcr-complex-specific antibodies and methods of using same
EP3067063A1 (en) 2008-04-02 2016-09-14 MacroGenics, Inc. Her2/neu-specific antibodies and methods of using same
CA2725873C (en) 2008-05-29 2018-05-01 Galaxy Biotech, Llc Monoclonal antibodies to basic fibroblast growth factor
BRPI0920573A8 (en) * 2008-10-10 2017-12-12 Emergent Product Dev Seattle IMMUNOTHERAPEUTIC TCR COMPLEXES
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
PL2365828T3 (en) 2008-11-07 2015-04-30 Galaxy Biotech Llc Monoclonal antibodies to fibroblast growth factor receptor 2
CN102573905A (en) * 2008-12-05 2012-07-11 勒帕斯公司 Antibody design using anti-lipid antibody crystal structures
US8401799B2 (en) * 2008-12-05 2013-03-19 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
US20100292443A1 (en) * 2009-02-26 2010-11-18 Sabbadini Roger A Humanized platelet activating factor antibody design using anti-lipid antibody templates
CA2758964A1 (en) 2009-04-16 2010-10-21 Abbott Biotherapeutics Corp. Anti-tnf-.alpha. antibodies and their uses
WO2010121093A2 (en) * 2009-04-17 2010-10-21 Lpath, Inc. Humanized antibody compositions and methods for binding lysophosphatidic acid
US9079953B2 (en) 2009-06-17 2015-07-14 Abbvie Biotherapeutics Inc. Anti-VEGF antibodies and their uses
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US8470980B2 (en) 2009-09-09 2013-06-25 Centrose, Llc Extracellular targeted drug conjugates
TR201804897T4 (en) 2009-10-07 2018-06-21 Macrogenics Inc POLYPEPTIDES CONTAINING FC REGION WITH ADVANCED EFFECTOR FUNCTION DUE TO CHANGES OF FUCOSILATION SIZE AND METHODS FOR THEIR USE
ES2788457T3 (en) 2009-10-23 2020-10-21 Millennium Pharm Inc Anti-GCC Antibody Molecules and Related Compositions and Methods
CN102753580A (en) 2009-10-28 2012-10-24 亚培生物医疗股份有限公司 Anti-egfr antibodies and their uses
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
PT2506871T (en) * 2009-11-30 2016-11-07 Janssen Biotech Inc Antibody fc mutants with ablated effector functions
WO2011084496A1 (en) 2009-12-16 2011-07-14 Abbott Biotherapeutics Corp. Anti-her2 antibodies and their uses
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
US20110212088A1 (en) * 2010-02-26 2011-09-01 Sabbadini Roger A Anti-paf antibodies
CN102892426B (en) 2010-03-04 2016-08-31 宏观基因有限公司 The antibody reactive with B7-H3, its immunologic competence fragment and application thereof
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
WO2011113019A2 (en) 2010-03-12 2011-09-15 Abbott Biotherapeutics Corp. Ctla4 proteins and their uses
WO2011153346A1 (en) 2010-06-03 2011-12-08 Genentech, Inc. Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
UA112062C2 (en) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх CD33-Binding Agent
KR102198189B1 (en) 2010-12-06 2021-01-05 시애틀 지네틱스, 인크. Humanized antibodies to liv-1 and use of same to treat cancer
MY163539A (en) 2011-03-29 2017-09-15 Roche Glycart Ag Antibody fc variants
EP2699256B1 (en) 2011-04-21 2017-09-27 The Regents of the University of Colorado, a body corporate Compositions and methods for the treatment of neuromyelitis optica
CN103687872A (en) 2011-04-22 2014-03-26 新兴产品开发西雅图有限公司 Prostate-specific membrane antigen binding proteins and related compositions and methods
UA115402C2 (en) * 2011-05-21 2017-10-25 Макродженікс, Інк. CD3-Binding Molecule Able to Bind to CD3 HUMAN AND NON-HUMAN CD3
MX347818B (en) 2011-05-21 2017-05-15 Macrogenics Inc Deimmunized serum-binding domains and their use for extending serum half-life.
EP2742953B1 (en) 2011-08-11 2021-09-22 ONO Pharmaceutical Co., Ltd. Therapeutic agent for autoimmune diseases comprising pd-1 agonist
LT3378535T (en) 2011-10-28 2023-02-27 Prothena Biosciences Limited Humanized antibodies that recognize alpha-synuclein
KR102246217B1 (en) 2012-01-27 2021-04-29 프로테나 바이오사이언시즈 리미티드 Humanized antibodies that recognize alpha-synuclein
SG10201608307WA (en) 2012-04-20 2016-11-29 Emergent Product Dev Seattle Cd3 binding polypeptides
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
PT2872534T (en) 2012-07-13 2018-10-26 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
AU2013318147B2 (en) 2012-09-19 2018-01-04 Abbvie Biotherapeutics Inc. Methods for identifying antibodies with reduced immunogenicity
UA118441C2 (en) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Antibodies recognizing alpha-synuclein
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
EA035943B1 (en) 2013-03-13 2020-09-03 Протена Биосайенсес Лимитед Antibody binding to human tau protein
RU2721707C2 (en) 2013-03-14 2020-05-21 Макродженикс, Инк. Bispecific molecules, immunoreactive with immune effector cells expressing an activating receptor
AU2014233478A1 (en) 2013-03-15 2015-09-24 Abbvie Biotechnology Ltd. Anti-CD25 antibodies and their uses
US20150010538A1 (en) 2013-03-15 2015-01-08 Abbvie Biotherapeutics Inc. Anti-cd25 antibodies and their uses
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
US9951131B2 (en) 2013-07-12 2018-04-24 Prothena Biosciences Limited Antibodies that recognize IAPP
WO2015004632A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize iapp
US11161906B2 (en) 2013-07-25 2021-11-02 Cytomx Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
UA116479C2 (en) 2013-08-09 2018-03-26 Макродженікс, Інк. Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
PL3041513T3 (en) 2013-09-08 2021-01-25 Kodiak Sciences Inc. Factor viii zwitterionic polymer conjugates
EP3071974A2 (en) 2013-11-19 2016-09-28 Prothena Biosciences Limited Monitoring immunotherapy of lewy body disease from constipation symptoms
DK3079719T3 (en) 2013-12-09 2019-11-18 Allakos Inc ANTI-SIGLEC-8 antibodies and methods for their use
JP2017506640A (en) 2014-02-14 2017-03-09 セントローズ, エルエルシー Extracellular targeted drug conjugates
WO2015131155A1 (en) 2014-02-28 2015-09-03 Allakos Inc. Methods and compositions for treating siglec-8 associated diseases
WO2015136471A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg1-3
TW201623331A (en) 2014-03-12 2016-07-01 普羅帝納生物科學公司 Anti-MCAM antibodies and associated methods of use
PT3116911T (en) 2014-03-12 2019-09-04 Prothena Biosciences Ltd Anti-mcam (cd146, muc16) antibodies and associated methods of use
US10059761B2 (en) 2014-03-12 2018-08-28 Prothena Biosciences Limited Anti-Laminin4 antibodies specific for LG4-5
JP2017510627A (en) 2014-03-13 2017-04-13 プロセナ バイオサイエンシーズ リミテッド Combined treatment of multiple sclerosis
JP6744856B2 (en) 2014-04-08 2020-08-19 プロセナ・バイオサイエンシズ・リミテッド Blood-brain barrier shuttle containing antibody that recognizes α-synuclein
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP7020909B2 (en) 2014-07-25 2022-02-16 シトムクス セラピューティクス,インコーポレイティド Anti-CD3 antibody, activating anti-CD3 antibody, multispecific anti-CD3 antibody, multispecific activating anti-CD3 antibody, and how to use them.
CA2959629C (en) 2014-09-03 2023-10-31 Boehringer Ingelheim International Gmbh Compound targeting il-23a and tnf-alpha and uses thereof
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
SG11201702544WA (en) 2014-09-29 2017-04-27 Univ Duke Bispecific molecules comprising an hiv-1 envelope targeting arm
JP6849590B2 (en) 2014-10-17 2021-03-24 コディアック サイエンシーズ インコーポレイテッドKodiak Sciences Inc. Butyrylcholinesterase amphoteric ionic polymer conjugate
CA2966005C (en) 2014-10-31 2021-04-27 Abbvie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
EP3221363B1 (en) 2014-11-21 2020-05-06 Bristol-Myers Squibb Company Antibodies against cd73 and uses thereof
SI3221346T1 (en) 2014-11-21 2020-11-30 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
WO2016106302A1 (en) 2014-12-23 2016-06-30 Bristol-Myers Squibb Company Antibodies to tigit
TWI769570B (en) 2015-01-28 2022-07-01 愛爾蘭商普羅佘納生物科技有限公司 Anti-transthyretin antibodies
TWI781507B (en) 2015-01-28 2022-10-21 愛爾蘭商普羅佘納生物科技有限公司 Anti-transthyretin antibodies
TWI718122B (en) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 Anti-transthyretin antibodies
EP3662933A1 (en) 2015-03-18 2020-06-10 Seattle Genetics, Inc. Cd48 antibodies and conjugates thereof
AU2016242866B2 (en) 2015-03-30 2021-06-03 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to FC gamma receptors
US10570191B2 (en) 2015-04-17 2020-02-25 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
CA2984249A1 (en) 2015-04-29 2016-11-03 Regeneron Pharmaceuticals, Inc. Treatment of fibrodysplasia ossificans progressiva
HUE061253T2 (en) 2015-05-29 2023-06-28 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof
TW201709932A (en) 2015-06-12 2017-03-16 西雅圖遺傳學公司 CD123 antibodies and conjugates thereof
AU2016278239B9 (en) 2015-06-17 2022-08-11 Allakos Inc. Methods and compositions for treating fibrotic diseases
SI3316909T1 (en) 2015-06-30 2023-10-30 Seagen Inc. Anti-ntb-a antibodies and related compositions and methods
GB201513033D0 (en) * 2015-07-23 2015-09-09 Ucb Biopharma Sprl Proteins
WO2017046776A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
KR20180053322A (en) 2015-09-21 2018-05-21 압테보 리서치 앤드 디벨롭먼트 엘엘씨 CD3 binding polypeptide
US10604577B2 (en) 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
KR20180069066A (en) 2015-10-30 2018-06-22 갤럭시 바이오테크, 엘엘씨 Extremely powerful antibodies that bind to death receptor 4 and death receptor 5
WO2017079369A2 (en) * 2015-11-03 2017-05-11 Glaxosmithkline Llc Novel antibodies
CA3003969A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
JP7088454B2 (en) 2015-12-30 2022-06-21 コディアック サイエンシーズ インコーポレイテッド Antibodies and antibody complexes
CN117024599A (en) 2016-02-05 2023-11-10 奥里尼斯生物科学私人有限公司 Bispecific signaling agents and uses thereof
KR20180107111A (en) 2016-02-17 2018-10-01 시애틀 지네틱스, 인크. BCMA antibodies and their uses for treating cancer and immunological disorders
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
CA3016187A1 (en) 2016-03-04 2017-09-08 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
MX2018012433A (en) 2016-04-15 2019-03-01 Macrogenics Inc Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof.
US11016085B2 (en) 2016-04-25 2021-05-25 The Johns Hopkins University ZNT8 assays for drug development and pharmaceutical compositions
EP3452509A1 (en) 2016-05-02 2019-03-13 Prothena Biosciences Limited Antibodies recognizing tau
KR102506091B1 (en) 2016-05-02 2023-03-07 프로테나 바이오사이언시즈 리미티드 Tau Immunotherapy
AU2017259038A1 (en) 2016-05-02 2018-10-11 Prothena Biosciences Limited Antibodies recognizing Tau
MX2018013072A (en) 2016-05-09 2019-03-21 Squibb Bristol Myers Co Tl1a antibodies and uses thereof.
AU2017271602A1 (en) 2016-05-27 2018-12-13 Abbvie Biotherapeutics Inc. Anti-CD40 antibodies and their uses
KR20190014525A (en) 2016-05-27 2019-02-12 애브비 바이오테라퓨틱스 인크. A bispecific binding protein that binds immuno-regulatory proteins to tumor antigens
EP3464362B1 (en) 2016-05-27 2020-12-09 AbbVie Biotherapeutics Inc. Anti-4-1bb antibodies and their uses
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
TWI640536B (en) 2016-06-20 2018-11-11 克馬伯有限公司 Antibodies
EP3478714A2 (en) 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2018007924A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
JP7016470B2 (en) 2016-07-02 2022-02-07 プロセナ バイオサイエンシーズ リミテッド Anti-transthyretin antibody
US9914783B1 (en) 2016-09-14 2018-03-13 Abbvie Biotherapeutics Inc. Anti-PD-1 antibodies and their uses
MY194290A (en) * 2016-09-21 2022-11-26 Aptevo Res & Development Llc CD123 Binding Proteins and Related Compositions and Methods
CA3045940A1 (en) 2016-12-15 2018-06-21 Abbvie Biotherapeutics Inc. Anti-ox40 antibodies and their uses
US10906985B2 (en) 2017-02-06 2021-02-02 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
US11584790B2 (en) 2017-04-14 2023-02-21 Kodiak Sciences Inc. Complement factor D antagonist antibodies and conjugates thereof
EA201992626A1 (en) 2017-05-05 2020-04-24 Аллакос Инк. METHODS AND COMPOSITIONS FOR TREATMENT OF ALLERGIC EYE DISEASES
BR112019024419A2 (en) 2017-05-25 2020-07-14 Bristol-Myers Squibb Company antibodies comprising modified heavy constant regions
US11892457B2 (en) 2017-07-12 2024-02-06 The Johns Hopkins University Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis
CN110945023B (en) 2017-07-31 2023-08-18 豪夫迈·罗氏有限公司 Humanization method based on three-dimensional structure
AU2017434556A1 (en) 2017-09-28 2020-04-09 F. Hoffmann-La Roche Ag Dosing regimes for treatment of synucleinopathies
WO2019074124A1 (en) 2017-10-12 2019-04-18 Keio University Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof
TW202340257A (en) 2018-02-09 2023-10-16 日商小野藥品工業股份有限公司 Bispecific antibody
EP3774916A2 (en) 2018-04-06 2021-02-17 Biolegend, Inc. Anti-tetraspanin 33 agents and compositions and methods for making and using the same
CN113840832A (en) 2018-05-14 2021-12-24 狼人治疗公司 Activatable interleukin-2 polypeptides and methods of use thereof
WO2019222296A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
BR112021003156A2 (en) 2018-08-23 2021-05-11 Seagen, Inc. composition, antibody that binds to human tigi, pharmaceutical formulation, isolated polynucleotide, vector, host cell, methods for producing an antibody that binds to human tigi and fucosylated antibodies that bind to tigi, and for the treatment of cancer , and, kit.
CN113365697A (en) 2018-09-25 2021-09-07 百进生物科技公司 anti-TLR9 agents and compositions and methods of making and using the same
CA3112989A1 (en) 2018-09-27 2020-04-02 Xilio Development, Inc. Masked cytokine polypeptides
TW202028246A (en) 2018-10-11 2020-08-01 美商英伊布里克斯公司 B7h3 single domain antibodies and therapeutic compositions thereof
CN113166262A (en) 2018-10-11 2021-07-23 英伊布里克斯公司 PD-1 single domain antibodies and therapeutic compositions thereof
TW202021986A (en) 2018-10-11 2020-06-16 美商英伊布里克斯公司 5t4 single domain antibodies and therapeutic compositions thereof
CN113166263A (en) 2018-10-11 2021-07-23 印希比股份有限公司 DLL3 single domain antibodies and therapeutic compositions thereof
JP7166457B2 (en) 2018-11-26 2022-11-07 フォーティ セブン, インコーポレイテッド Humanized antibody against c-Kit
CA3120570A1 (en) 2018-11-28 2020-06-04 Forty Seven, Inc. Genetically modified hspcs resistant to ablation regime
US20220106400A1 (en) 2018-11-28 2022-04-07 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
CA3122773A1 (en) 2018-12-26 2020-07-02 Xilio Development, Inc. Anti-ctla4 antibodies and methods of use thereof
WO2020163225A1 (en) 2019-02-05 2020-08-13 Seattle Genetics, Inc. Anti-cd228 antibodies and antibody-drug conjugates
CA3131531A1 (en) 2019-03-03 2020-09-10 Prothena Biosciences Limited Antibodies recognizing tau
WO2020213084A1 (en) 2019-04-17 2020-10-22 Keio University Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof
MX2021013766A (en) 2019-05-14 2022-02-21 Werewolf Therapeutics Inc Separation moieties and methods and use thereof.
EP3984554A4 (en) 2019-06-11 2023-11-08 ONO Pharmaceutical Co., Ltd. Immunosuppression agent
CA3142513A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
AU2020358859A1 (en) 2019-10-04 2022-05-12 Seagen Inc. Anti-PD-L1 antibodies and antibody-drug conjugates
CN114786731A (en) 2019-10-10 2022-07-22 科达制药股份有限公司 Methods of treating ocular disorders
CN113005088A (en) * 2019-12-19 2021-06-22 苏州方德门达新药开发有限公司 Engineered T cells, their preparation and use
CN115052663A (en) 2020-01-08 2022-09-13 辛瑟斯治疗股份有限公司 ALK5 inhibitor conjugates and uses thereof
US20210253685A1 (en) 2020-01-08 2021-08-19 Regeneron Pharmaceuticals, Inc. Treatment of fibrodysplasia ossificans progressiva
WO2021146383A1 (en) 2020-01-17 2021-07-22 BioLegend, Inc. Anti-tlr7 agents and compositions and methods for making and using the same
US20230126689A1 (en) 2020-03-06 2023-04-27 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
CN115698069A (en) 2020-03-26 2023-02-03 思进公司 Methods of treating multiple myeloma
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
CN115698068A (en) 2020-06-02 2023-02-03 艾库斯生物科学有限公司 anti-TIGIT antibody
KR20230039734A (en) 2020-07-23 2023-03-21 오타이르 프로테나 리미티드 anti-Aβ antibody
WO2022031652A1 (en) 2020-08-04 2022-02-10 Seagen Inc. Anti-cd228 antibodies and antibody-drug conjugates
CN116157416A (en) 2020-08-25 2023-05-23 吉利德科学公司 HIV-targeting multispecific antigen-binding molecules and methods of use thereof
TWI815194B (en) 2020-10-22 2023-09-11 美商基利科學股份有限公司 INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE
WO2022093640A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2c agents and compositions and methods for making and using the same
WO2022093641A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2a agents and compositions and methods for making and using the same
WO2022098972A1 (en) 2020-11-08 2022-05-12 Seagen Inc. Combination-therapy antibody drug conjugate with immune cell inhibitor
TW202237639A (en) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof
TW202237638A (en) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof
WO2022172085A2 (en) 2021-02-15 2022-08-18 Takeda Pharmaceutical Company Limited Cell therapy compositions and methods for modulating tgf-b signaling
AU2022230384A1 (en) 2021-03-01 2023-09-07 Xilio Development, Inc. Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
WO2022187270A1 (en) 2021-03-01 2022-09-09 Xilio Development, Inc. Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
EP4301782A1 (en) 2021-03-05 2024-01-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
KR20230156079A (en) 2021-03-09 2023-11-13 젠코어 인코포레이티드 Heterodimeric antibody binding to CD3 and CLDN6
US11859012B2 (en) 2021-03-10 2024-01-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and GPC3
KR20230165911A (en) 2021-04-09 2023-12-05 씨젠 인크. Methods for treating cancer using anti-TIGIT antibodies
US20220389394A1 (en) 2021-05-18 2022-12-08 Gilead Sciences, Inc. METHODS OF USING FLT3L-Fc FUSION PROTEINS
CA3228178A1 (en) 2021-08-05 2023-02-09 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
CA3230933A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-lamp1 antibodies and their uses
WO2023034569A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
TW202327650A (en) 2021-09-23 2023-07-16 美商思進公司 Methods of treating multiple myeloma
WO2023215719A1 (en) 2022-05-02 2023-11-09 Arcus Biosciences, Inc. Anti-tigit antibodies and uses of the same
WO2024020051A1 (en) 2022-07-19 2024-01-25 BioLegend, Inc. Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
WO2024040114A2 (en) 2022-08-18 2024-02-22 BioLegend, Inc. Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9206422D0 (en) * 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US6129914A (en) * 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies

Also Published As

Publication number Publication date
PT966485E (en) 2008-12-10
JP2007106771A (en) 2007-04-26
AU3208397A (en) 1997-12-09
JP3947570B2 (en) 2007-07-25
CN1222162A (en) 1999-07-07
JP2002506420A (en) 2002-02-26
US5834597A (en) 1998-11-10
AU725821B2 (en) 2000-10-19
DE69738984D1 (en) 2008-10-23
EP0966485B1 (en) 2008-09-10
CN100549031C (en) 2009-10-14
EP0966485A1 (en) 1999-12-29
ATE407952T1 (en) 2008-09-15
ES2313736T3 (en) 2009-03-01
WO1997044362A1 (en) 1997-11-27
EP0966485A4 (en) 2005-01-19
CA2255826C (en) 2002-10-01

Similar Documents

Publication Publication Date Title
CA2255826A1 (en) Mutated nonactivating igg2 domains and anti-cd3 antibodies incorporating the same
DE69531679D1 (en) FOR E-SELECTIN AND P-SELECTIN-SPECIFIC CROSS-REACTIVE MONOCLONAL ANTIBODIES
CA2172376A1 (en) Antibodies to cd40
IE85350B1 (en) Human notch and delta, binding domains in toporythmic¹proteins, and methods based thereon
CA2209172A1 (en) Murine monoclonal anti-idiotype antibody 3h1
CA2429027A1 (en) Antibodies against human receptor h4-1bb
CA2104899A1 (en) Antibodies to Plasmodium Falciparum
HK1044159A1 (en) Humanized antibodies to gamma-interferon
AU7566991A (en) Monoclonal antibody and immunoconjugates for the treatment and detection of b cell disorders
AU6113396A (en) Novel high affinity human antibodies to tumor antigens
DE69021953T2 (en) Enzyme immunoassay for antigens and solid phase that can be used for them.
HU9800744D0 (en) Anti-fas antibodies
WO2002034290A3 (en) Antibodies and other ligands directed against kir2dl4 receptor for production of interferon gamma
EP0749445A4 (en) Antibodies which bind the g-csf receptor extracellular domain and methods of treatment
EP0714510A4 (en) Natural killer cell-specific antigen and antibodies that identify the same
CA2157500A1 (en) Lo-cd2a antibody and uses thereof for inhibiting t-cell activation and proliferation
NO972522L (en) Monoclonal antibodies with immunosuppressive activity
EP0297930A3 (en) Monoclonal antibodies
FI954827A (en) Immune particles carrying anti-CD4 monoclonal antibodies and their use
WO1992004464A3 (en) Monoclonal antibodies against tenascin
CA2088889A1 (en) Specific antibodies against activated platelets, the preparation thereof and the use thereof in diagnosis and therapy
AU2828795A (en) Monoclonal antibodies for the reduction of anti-xenogeneic immune responses
DK0889907T3 (en) Monoclonal antibodies that bind human growth hormone (hGH)
AU4775899A (en) Human monoclonal antibodies against the tumor antigen uk114 and lymphocyte cellsand hybridomas for their production
AU1915395A (en) Antibodies which bind the g-csf receptor extracellular domain and methods of treatment

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20170519